Atlas Bio
As of 27 Oct 2026, Atlas Bio has raised $10M across 1 verified round on record; latest: $10 million seed round led by Creandum, announced 27 Oct 2026.
As of 27 Oct 2026, Atlas Bio has raised $10M across 1 verified round on record; latest: $10 million seed round led by Creandum, announced 27 Oct 2026.
4 sources · checked 1 time, last 1h ago
The supplied source identifies the company and amount, but states no stage, valuation, financing total, investors, or headquarters.; not on the page it cites, so not applied: date
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Seed | $10M $12.5M to date | 2026-10-27 | Creandum | 4 outlets. #33 in Trending |
4 sources · checked 1 time, last 1h ago [ VERIFIED ] read against 1 of 4 sources The supplied source identifies the company and amount, but states no stage, valuation, financing total, investors, or headquarters.; not on the page it cites, so not applied: date | ||||
Atlas Bio runs in-silico clinical trials using a foundation AI model of human biology to predict and compare patient responses for biopharma teams deciding what treatments, indications, or assets to advance.
Atlas is targeting a costly bottleneck in drug development: the company says Phase II trials can cost more than $100 million, take two to three years, and see around 70% of drugs fail, while animal models are a poor proxy for human biology. Its model is trained on roughly 2 million human RNA readouts and can run 12-week virtual trials across patient profiles, and the $12.5 million raised is intended to scale validation, scientific and commercial teams, and enterprise-client onboarding.
Also named as backers in company research: First Momentum Ventures, LEA Partners